Table 1: Baseline clinical characteristics of the study cohort.
|
Characteristic |
Total n = 106 |
|
Age, years |
|
|
Mean (SD) |
66.2 (10.0) |
|
Median (range) |
67 (31–88) |
|
Gender, n (%) |
|
|
Male |
57 (53.8) |
|
Female |
49 (46.2) |
|
Stage at enrollment, n (%) |
|
|
IIIA |
10 (9.4) |
|
IIIB |
8 (7.6) |
|
IV |
88 (83) |
|
Histology, n (%) |
|
|
Adenocarcinoma |
84 (79.2) |
|
Carcinoma NOS |
2 (1.9) |
|
NSCLC |
11 (10.4) |
|
SCLC |
3 (2.8) |
|
SQ |
4 (3.8) |
|
No histology |
2 (1.9) |
|
Status of disease, n (%) |
|
|
Initially diagnosed |
89 (84.0) |
|
Recurrence |
8 (7.5) |
|
On-treatment |
9 (8.5) |
|
ECOG performance status, n (%) |
|
|
0 |
29 (27.3) |
|
1 |
44 (41.5) |
|
2 |
15 (14.2) |
|
3 |
3 (2.8) |
|
Unknown |
15 (14.2) |
|
EGFR gene, n (%) |
|
|
Positive |
18 (17.0) |
|
Negative |
62 (58.5) |
|
Unknown |
26 (24.5) |
|
Smoking, n (%) |
|
|
Never |
21 (19.8) |
|
Former |
17 (16.0) |
|
Current |
35 (33.0) |
|
Unknown |
33 (31.2) |
SD: Standard Deviation;
NOS: Not Otherwise Specified;
NSCLC: Non-Small Cell Lung Cancer;
SCLS: Small Cell Lung Cancer;
SQ: Squamous Cell Carcinoma;
ECOG: Eastern Cooperative Oncology Group;
EGFR : Epidermal Growth Factor Receptor